A number of other research analysts also weighed in on the company. HC Wainwright lowered its price target on Taro Pharmaceutical Industries from $75.00 to $73.00 and set a “buy” rating on the stock in a Monday, January 31 report. Zacks Investment Research downgraded Taro Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Friday, January 21. Finally, TheStreet downgraded Taro Pharmaceutical Industries from a “c” rating to a “d+” rating in a Wednesday, November 24 report.
TARO shares traded at $0.01 during Friday’s midday session, hitting $45.50. 31,904 shares of the company were traded, compared to its average volume of 19,242. The stock’s 50-day moving average is $47.19 and its two-hundred-day moving average is $54.56 . The stock has a market capitalization of $1.71 billion, a P/E ratio of 1,137.78 and a beta of 0.75. Taro Pharmaceutical Industries has a 12-month low of $43.29 and a 12-month high of $79.24.
Taro Pharmaceutical Industries (NYSE: TARO – Get a rating) last reported results on Thursday, January 27. The company reported EPS of $0.70 for the quarter, missing analyst consensus estimates of $0.91 per ($0.21). Taro Pharmaceutical Industries posted a net margin of 0.19% and a return on equity of 7.33%. In the same quarter a year earlier, the company posted EPS of $0.86. As a group, equity research analysts expect Taro Pharmaceutical Industries to post EPS of 3.33 for the current year.
Several institutional investors and hedge funds have recently increased or reduced their stake in the company. Invesco Ltd. increased its position in shares of Taro Pharmaceutical Industries by 44.7% in the third quarter. Invesco Ltd. now owns 259,059 shares of the company worth $16,484,000 after acquiring an additional 79,983 shares last quarter. Norges Bank acquired a new position in shares of Taro Pharmaceutical Industries during the 4th quarter for a value of $3,046,000. murchinson ltd. increased its stake in shares of Taro Pharmaceutical Industries by 59.2% during the 4th quarter. murchinson ltd. now owns 159,203 shares of the company worth $7,978,000 after acquiring an additional 59,203 shares last quarter. Morgan Stanley increased its stake in shares of Taro Pharmaceutical Industries by 226.0% in the second quarter. Morgan Stanley now owns 49,013 shares of the company worth $3,527,000 after buying an additional 33,979 shares in the last quarter. Finally, Parametric Portfolio Associates LLC increased its stake in Taro Pharmaceutical Industries by 26.5% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 60,545 shares of the company valued at $4,357,000 after purchasing an additional 12,700 shares in the last quarter. 12.10% of the shares are currently held by institutional investors.
Taro Pharmaceutical Industries Company Profile (Get a rating)
Taro Pharmaceutical Industries Ltd. is engaged in the development, manufacture and marketing of prescription and over-the-counter pharmaceutical products in the United States, Canada and Israel. Its products include semi-solid formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets, in dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapy categories.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Taro Pharmaceutical Industries right now?
Before you consider Taro Pharmaceutical Industries, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Taro Pharmaceutical Industries was not on the list.
Although Taro Pharmaceutical Industries currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here